Explain current testing types, strategies, and recommendations for molecular testing of patients with NSCLC and how they inform treatment decision-making for patients with EGFR alterations, particularly exon 19 and 21 Survey recent trial data regarding the safety and eïcacy data of targeted therapies and combinations for NSCLC patients with EGFR exon 19 and 21 alterations Outline optimal treatment plans in both the adjuvant and advanced settings for NSCLC patients with EGFR exon 19 and 21 alterations and approaches to eìectively communicate treatment goals and considerations with patients Appraising strategies to identify and mitigate TRAEs associated with anti-EGFR targeted therapies within MDC teams
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2025-01-03 06:00:00
- End Date: 2025-01-03 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest